Skip to main content
Growth HormoneGHRH analog

Tesamorelin

Also known as: Egrifta, Egrifta SV, Egrifta WR, TH9507

By the Peptide Dossier Editorial TeamUpdated How we source

Tesamorelin is a GHRH analog used in specific EGRIFTA formulations for excess abdominal fat in adults with HIV-associated lipodystrophy. General weight-loss, anti-aging and compounded-wellness uses are separate from that approved indication.

Quick Facts

Class:GHRH analog
US product context:Specific EGRIFTA products are FDA-approved for excess abdominal fat in adults with HIV-associated lipodystrophy; not general weight-loss management.
Evidence context:Randomized evidence supports visceral-fat reduction in HIV lipodystrophy; broader wellness uses and additional research indications remain distinct.

Identity and approved use

Tesamorelin, developed as TH9507, is a stabilized synthetic growth-hormone-releasing-hormone analog. It was approved in the United States in 2010 as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. EGRIFTA SV and WR are later formulations. The label does not indicate general weight-loss management. The distinction between a research compound and a medicine is covered in our guide to FDA approval.

Sources: [5]

Pituitary signaling and visceral fat

Binding pituitary GHRH receptors promotes endogenous, pulsatile GH secretion and increases IGF-1. Growth hormone has anabolic and lipolytic actions, with visceral fat particularly responsive in the approved HIV population. Stimulating the pituitary instead of injecting GH does not establish a universal safety advantage or eliminate GH/IGF-1-related risks. Our overview of peptide safety explains how to read uncertainty around benefits and risks.

Tesamorelin visceral-fat trial context
Trial group/timeVisceral adipose tissue change
Tesamorelin at six monthsApproximately −11%; one supplied trial reports −10.9%.
Placebo at six monthsLittle change; −0.6% in that trial.
Continued treatment to 12 monthsReduction approaching 18%.

These percentages describe visceral adipose tissue, not total body-weight loss. Fat tends to reaccumulate after stopping treatment.

Sources: [1], [2], [10]

Randomized evidence and persistence

In a Phase III study of 412 adults with HIV, visceral fat fell 15.2% on tesamorelin while increasing 5.0% with placebo at 26 weeks (p < 0.001). A pooled analysis of two trials including 806 antiretroviral-treated adults found a CT-measured visceral-fat treatment effect of approximately −15.4% at 26 weeks; abdominal subcutaneous-fat change was not significant. A separate supplied account of a 404-person randomized trial also reports lower visceral fat and higher IGF-1 without a mean glucose difference.

Extension observations through 52 weeks supported persistence during continued treatment and reaccumulation after withdrawal. Historical studies used a 2 mg research regimen. Their trial schedule and favorable average findings do not replace current product labeling.

Non-HIV visceral adiposity and HIV-associated fatty-liver studies exist, but the source identifies no dedicated controlled program establishing general non-HIV wellness/body-composition or anti-aging use. That marketing context is extrapolated rather than an approved indication. Tesamorelin is prohibited at all times under WADA’s GHRH-analog rules.

Sources: [4], [6], [8], [9]

Current formulation-specific dosing and handling

The existing reviewed EGRIFTA WR label specifies 1.28 mg subcutaneously once daily from an 11.6 mg vial. The EGRIFTA SV label specifies 1.4 mg once daily from a 2 mg vial. Vial strength is not the administered dose, and WR and SV are not substitutable.

WR is mixed with its supplied bacteriostatic water, kept at room temperature after mixing and discarded after seven days. SV uses its supplied sterile water and is administered immediately after mixing, with the remainder discarded. Unmixed vials use controlled room-temperature storage under their exact labels. A universal refrigeration rule or 30-day mixed-vial lifetime is inappropriate. These instructions do not validate a different compounded preparation.

Sources: [3], [14], [15]

Safety, contraindications and metabolic monitoring

Contraindications include pregnancy, active malignancy, known hypersensitivity and disruption of the hypothalamic-pituitary axis, including hypopituitarism, pituitary tumor, prior head irradiation or head trauma. Prior cancer should be inactive and fully treated before treatment is considered. Warnings address possible neoplasms, elevated IGF-1, glucose intolerance/diabetes, fluid retention and allergic reactions; long-term cardiovascular safety has not been established.

Common trial effects included injection-site redness, itching or pain, arthralgia, muscle/limb pain, peripheral edema and paresthesia. Hypersensitivity occurred in 4% of trial patients. IGF-1 and glucose require monitoring.

Average glucose outcomes and diabetes-range events are different endpoints. The pooled 806-person trials did not find clinically meaningful mean glucose differences; a 12-week randomized study of 53 adults with type 2 diabetes similarly found no significant fasting-glucose or insulin-response differences. Nevertheless, an HbA1c of at least 6.5% by week 26 occurred in 5% on tesamorelin versus 1% on placebo. GH can counter insulin action, so favorable group averages do not remove the monitoring requirement.

Sources: [11], [12]

Additional liver and cognitive research retained

The existing 12-month HIV/NAFLD trial found a favorable liver-fat outcome with an absolute between-group effect of −4.1 percentage points. That population and endpoint do not establish a general liver-disease treatment or long-term histological improvement.

A 20-week cognitive study enrolled 152 older adults, including 66 with mild cognitive impairment. Executive-function findings were favorable, while verbal memory showed a nonsignificant trend (P = 0.08). A 2026 pilot involving 22 participants found no direct significant changes in its study measures; machine-learning imaging analyses were exploratory. These observations do not establish dementia prevention or routine cognitive treatment.

Sources: [7], [17], [18]

References and further reading

This reference draws on Superpower reference 1, Superpower reference 2 and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .

  1. dailymed.nlm.nih.govPituitary signaling and visceral fatCited in: Pituitary signaling and visceral fat
  2. 10.1097/QAI.0b013e3181cbdaffPituitary signaling and visceral fatCited in: Pituitary signaling and visceral fat
  3. dailymed.nlm.nih.govCurrent formulation-specific dosing and handlingCited in: Current formulation-specific dosing and handling
  4. 10.1097/QAD.0b013e32830a5058Randomized evidence and persistenceCited in: Randomized evidence and persistence
  5. accessdata.fda.govIdentity and approved useCited in: Identity and approved use
  6. pubmed.ncbi.nlm.nih.govRandomized evidence and persistenceCited in: Randomized evidence and persistence
  7. pubmed.ncbi.nlm.nih.govAdditional liver and cognitive research retainedCited in: Additional liver and cognitive research retained
  8. pubmed.ncbi.nlm.nih.govRandomized evidence and persistenceCited in: Randomized evidence and persistence
  9. pubmed.ncbi.nlm.nih.govRandomized evidence and persistenceCited in: Randomized evidence and persistence
  10. pubmed.ncbi.nlm.nih.govPituitary signaling and visceral fatCited in: Pituitary signaling and visceral fat
  11. pubmed.ncbi.nlm.nih.govSafety, contraindications and metabolic monitoringCited in: Safety, contraindications and metabolic monitoring
  12. dailymed.nlm.nih.govSafety, contraindications and metabolic monitoringCited in: Safety, contraindications and metabolic monitoring
  13. pubmed.ncbi.nlm.nih.govFrequently asked questionsCited in: Frequently asked questions
  14. dailymed.nlm.nih.gov — additional readingCurrent formulation-specific dosing and handlingCited in: Current formulation-specific dosing and handling
  15. dailymed.nlm.nih.gov — additional readingCurrent formulation-specific dosing and handlingCited in: Current formulation-specific dosing and handling
  16. pubmed.ncbi.nlm.nih.gov — additional reading
  17. pubmed.ncbi.nlm.nih.gov — additional readingAdditional liver and cognitive research retainedCited in: Additional liver and cognitive research retained
  18. pubmed.ncbi.nlm.nih.gov — additional readingAdditional liver and cognitive research retainedCited in: Additional liver and cognitive research retained

Frequently Asked Questions About Tesamorelin

Specific EGRIFTA products reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Their labels do not indicate general weight-loss management.

Tesamorelin stimulates endogenous GH rather than supplying GH directly. That distinction does not establish a universal comparative safety or efficacy advantage.

Phase-3 research measured visceral-fat outcomes at 26 weeks, with extensions through 52 weeks. It does not establish a fixed visible-results schedule for every reader.

Check the exact product. WR and SV unmixed vials use controlled room-temperature storage; mixed WR is used over seven days at room temperature, whereas SV is used immediately after mixing. Their instructions are not substitutable.

Specific EGRIFTA products reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Studies in non-HIV visceral adiposity or HIV-related fatty liver do not make those separate uses approved.

Pivotal studies measured outcomes at 26 weeks. One 412-person trial reported −15.2% visceral fat versus +5.0% with placebo; the pooled 806-person treatment effect was approximately −15.4%. These are visceral-fat, not body-weight, percentages.

Yes. GH-axis stimulation may impair insulin sensitivity. Some trials found no significant mean glucose difference, yet HbA1c reaching at least 6.5% by week 26 was more frequent with tesamorelin (5% versus 1%). Baseline and ongoing glucose monitoring matter.

Tesamorelin is a full-length GHRH (1–44) analog with an N-terminal trans-3-hexenoyl modification that resists DPP-IV breakdown. Sermorelin is the shorter unstabilized GHRH (1–29) sequence. Tesamorelin has Phase III evidence for HIV lipodystrophy; sermorelin’s historical Geref approval ended after discontinuation. No published head-to-head comparison is described in these reports.

Sources: [13]

Contraindications include active cancer, pregnancy, hypersensitivity and specified hypothalamic-pituitary disruption such as pituitary tumor, hypopituitarism, prior head irradiation or head trauma. Eligibility requires the prescriber’s complete evaluation.

Injection-site reactions, joint/muscle/limb pain, edema and paresthesia were common trial findings. Elevated IGF-1, glucose dysregulation and hypersensitivity need monitoring; hypersensitivity occurred in 4% of trial participants.

Extension studies found sustained reduction during continued use and fat reaccumulation toward baseline after withdrawal. Long-term decisions depend on clinical response, IGF-1, glucose and individualized benefit-risk assessment.

No. Tesamorelin stimulates endogenous GH rather than supplying GH itself. That mechanism does not prove it is always safer or more effective than HGH.

Follow the exact product label: unmixed WR and SV vials use controlled room-temperature storage; mixed WR is used at room temperature over seven days, while mixed SV is administered immediately. Their mixing and storage instructions are not substitutable.

Related Peptides

Continue exploring Tesamorelin

Search all related references →

Our library review is ongoing. Read how we evaluate evidence or report a correction.

Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.